249
Participants
Start Date
July 27, 2022
Primary Completion Date
December 1, 2026
Study Completion Date
December 1, 2026
Pembrolizumab
Pembrolizumab 400 mg administered Q6W via IV infusion
Belzutifan
Belzutifan 120 mg administered QD via oral tablet
Pembrolizumab/Quavonlimab
Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
Lenvatinib
Lenvatinib 20 mg administered QD via oral capsule
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000), Beijing
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S, Nanjing
The Second Affiliated Hospital of Soochow University-Urology ( Site 6025), Suzhou
The Second Hospital of Tianjin Medical University ( Site 6032), Tianjin
The First Affiliated Hospital, Zhejiang University ( Site 6024), Hangzhou
The First Hospital of Jiaxing ( Site 6033), Jiaxing
Ningbo First Hospital-Urology ( Site 6028), Ningbo
The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 6021), Wenzhou
The First Affiliated Hospital of Nanchang University ( Site 6019), Nanchang
Chongqing University Cancer Hospital ( Site 6009), Chongqing
Wuhan Union Hospital ( Site 6002), Wuhan
Henan Cancer Hospital-Urology ( Site 6006), Zhengzhou
SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003), Guangzhou
The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036), Guangzhou
Guangzhou First People's Hospital ( Site 6007), Guangzhou
West China Hospital Sichuan University-Urology Surgery ( Site 6016), Chengdu
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 6014), Xi'an
Eisai Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY